Luis M. Vilá to Glucocorticoids
This is a "connection" page, showing publications Luis M. Vilá has written about Glucocorticoids.
Connection Strength
0.644
-
Fajardo-Hermosillo LD, Rodr?guez-Navedo Y, Nadal AJ, Vil? LM. Lymphocyte sensitivity assay as a marker for glucocorticoid resistance in lupus: report of two sisters with systemic lupus erythematosus. Lupus. 2014; 23(1):88-92.
Score: 0.406
-
Santiago-Casas Y, Gonz?lez-Rivera TC, Castro-Santana LE, R?os G, Mart?nez D, Rodr?guez VE, Gonz?lez-Alcover R, Mayor AM, Vil? LM. Impact of age on clinical manifestations and outcome in Puerto Ricans with rheumatoid arthritis. Ethn Dis. 2010; 20(1 Suppl 1):S1-191-5.
Score: 0.078
-
Vil? LM, Molina MJ. Chronic anemia and thrombocytosis as the initial presentation of Still's disease in an elderly patient. Gerontology. 2007; 53(5):289-92.
Score: 0.065
-
Bertoli AM, Font YM, Nadal A, Vil? LM. Differences between active treatment and placebo groups in the study of induction treatment of giant cell arteritis with high-dose glucocorticoids: comment on the article by Mazlumzadeh et al. Arthritis Rheum. 2007 May; 56(5):1723; author reply 1723-4.
Score: 0.064
-
Andrade R, Sanchez ML, Alarc?n GS, Fessler BJ, Fern?ndez M, Bertoli AM, Apte M, Vil? LM, Arango AM, Reveille JD. Adverse pregnancy outcomes in women with systemic lupus erythematosus from a multiethnic US cohort: LUMINA (LVI) [corrected]. Clin Exp Rheumatol. 2008 Mar-Apr; 26(2):268-74.
Score: 0.017
-
Calvo-Al?n J, McGwin G, Toloza S, Fern?ndez M, Roseman JM, Bastian HM, Cepeda EJ, Gonz?lez EB, Baethge BA, Fessler BJ, Vil? LM, Reveille JD, Alarc?n GS. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study. Ann Rheum Dis. 2006 Jun; 65(6):785-90.
Score: 0.015